Abstract:OBJECTIVE:To develop human papillomavirus (HPV) 16 DNA vaccine for the treatment of HPV16 infection and its related tumors.METHODS:HPV16 oncogene E7 was modified by combined approaches including insertion and replication of specific region of E7 gene, murine codon optimization, and point-mutation at transforming regions of the E7 protein. The resulting artificial gene, named as mE7, was obtained by gene synthesis. The mE7 gene was then genetically fused to murine CD40 ligand (CD40L) by overlapping PCR to form the mE7/CD40L fusion gene. The mE7/CD40L gene was inserted into pVR1012 plasmid and then immunized C57/BL6 mice intramuscularly. The E7-specific IFN-gamma-secreting CD8+ T cells were analyzed with EIISPOT, and E7-specific antibody was measured by indirect ELISA. FACS assays were performed to analyze the activation of E7-specific Th cells. Mice were vaccinated, followed by tumor challenged or challenged before immunization. Tumor growth was observed.RESULTS:The mE7 DNA vaccine elicited an increased E7-specific antibody level (P < 0.01), E7-specific IFN-gamma-secreting CD8+ T (P < 0.01), and CD4+ T cells number (P < 0.05), compared with those of mice immunized with wE7 gene. Furthermore, the mE7/CD40L DNA vaccine elicited an increased number of E7-specific IFN-gamma secreting CD8+ T cell compared with that of mice immunized with mE7 gene (P < 0.01); however, no significant differences were found between mice immunized with the mE7 gene and mE7/CD40L fusion gene in the E7-specific antibody production and Th cell activation. In the preventive experiment, all mice received the mE7 or mE7/CD40L remained tumor-free 7 weeks after challenges with TC-1 tumor cells, while the wE7 group exhibited tumor growth within 2 weeks. In the therapeutic experiment, all the mice in the wE7 group exhibited tumor growth within 8 days, while among mice receiving the mE7 and mE7/CD40L, 30% and 45% of mice remained tumor-free after TC-1 challenge, respectively. HE staining of tumor tissues showed copious lymphocytes infiltration around tumor cells in mE7 and mE7/CD40L mice with regression of tumor growth.CONCLUSIONS:The mE7 DNA vaccine increases the E7-specific humoral and cellular immune responses, and the fusion of CD40L to mE7 gene enhances the specific immune responses and anti-tumor effects against HPV16 E7-expressing murine tumors. mE7/CD40L may therefore be a suitable and promising target for HPV16 therapeutic vaccine.

Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity.

Effects of Human Papillomavirus Type 16 E7 Protein on the Growth of Cervical Carcinoma Cells and Immuno-Escape Through the TGF-β1 Signaling Pathway

Linkage of Modified Human Papillomavirus Type 16 E7 to CD40 Ligand Enhances Specific CD8 + T-lymphocyte Induction and Anti-tumour Activity of DNA Vaccine

Digital RNA Sequencing of Human Epidermal Keratinocytes Carrying Human Papillomavirus Type 16 E7

[Cloning of Human Papillomavirus Type 16 E7 Gene and Expression in E. Coli].

Fungal Mannosylation Enhances Human Papillomavirus 16 E7 Therapeutic Immunity Against TC-1 Tumors.

Human HSP70 and Modified HPV16 E7 Fusion DNA Vaccine Induces Enhanced Specific CD8+ T Cell Responses and Anti-Tumor Effects.

[Cloning and Expressing of Human Papillomavirus 16 E7C Subgene].

A Novel Mutant of Human Papillomavirus Type 18 E6E7 Fusion Gene and Its Transforming Activity.

Study on Antitumor Effect of DC Vaccine Containing Mutant of HPV16 E6 E7 Fusion Gene

Transforming Activity of a Novel Mutant of HPV16 E6E7 Fusion Gene

Study on Immunuogenicity of HPV 16 E7 Variant

A Therapeutic DNA Vaccine Targeting HPV16 E7 in Combination with Anti-PD-1/PD-L1 Enhanced Tumor Regression and Cytotoxic Immune Responses

Cervical Cancer-Associated Human Papillomavirus 16 E7 Oncoprotein Inhibits Induction of Anti-Cancer Immunity by a CD4+ T Cell Dependent Mechanism

HPV16 mutant E6/E7 construct is protective in mouse model

Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.

De-oncogenic HPV E6/E7 Vaccine Gets Enhanced Antigenicity and Promotes Tumoricidal Synergy with Cisplatin

Hpv E7 Inhibits Cell Pyroptosis By Promoting Trim21-Mediated Degradation And Ubiquitination Of The Ifi16 Inflammasome

Vaccination of Full-Length HPV16 E6 or E7 Protein Inhibits the Growth of HPV16 Associated Tumors

A Point Mutation in the DNA-binding Domain of HPV-2 E2 Protein Increases Its DNA-binding Capacity and Reverses Its Transcriptional Regulatory Activity on the Viral Early Promoter.

Induction of Co-Inhibitory Molecule CTLA-4 by Human Papillomavirus E7 Protein Through Downregulation of Histone Methyltransferase JHDM1B Expression